- Home
- DNTH vs UFCS Comparison
DNTH vs UFCS Comparison
Compare DNTH & UFCS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DNTH
- UFCS
- Stock Information
- Founded
- DNTH 2015
- UFCS 1946
- Country
- DNTH United States
- UFCS United States
- Employees
- DNTH N/A
- UFCS N/A
- Industry
- DNTH Biotechnology: Pharmaceutical Preparations
- UFCS Property-Casualty Insurers
- Sector
- DNTH Health Care
- UFCS Finance
- Exchange
- DNTH Nasdaq
- UFCS Nasdaq
- Market Cap
- DNTH 724.8M
- UFCS 679.4M
- IPO Year
- DNTH N/A
- UFCS N/A
- Fundamental
- Price
- DNTH $23.67
- UFCS $25.47
- Analyst Decision
- DNTH Strong Buy
- UFCS Hold
- Analyst Count
- DNTH 9
- UFCS 1
- Target Price
- DNTH $46.43
- UFCS $28.00
- AVG Volume (30 Days)
- DNTH 198.9K
- UFCS 156.6K
- Earning Date
- DNTH 03-20-2025
- UFCS 02-11-2025
- Dividend Yield
- DNTH N/A
- UFCS 2.51%
- EPS Growth
- DNTH N/A
- UFCS N/A
- EPS
- DNTH N/A
- UFCS 2.39
- Revenue
- DNTH $5,366,000.00
- UFCS $1,253,307,000.00
- Revenue This Year
- DNTH $100.14
- UFCS N/A
- Revenue Next Year
- DNTH N/A
- UFCS $9.59
- P/E Ratio
- DNTH N/A
- UFCS $10.66
- Revenue Growth
- DNTH 51.41
- UFCS 14.41
- 52 Week Low
- DNTH $18.35
- UFCS $18.04
- 52 Week High
- DNTH $33.77
- UFCS $31.70
- Technical
- Relative Strength Index (RSI)
- DNTH 53.31
- UFCS 44.80
- Support Level
- DNTH $22.77
- UFCS $24.57
- Resistance Level
- DNTH $25.46
- UFCS $27.54
- Average True Range (ATR)
- DNTH 1.49
- UFCS 0.96
- MACD
- DNTH 0.13
- UFCS 0.17
- Stochastic Oscillator
- DNTH 57.18
- UFCS 32.23
About DNTH Dianthus Therapeutics Inc.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
About UFCS United Fire Group Inc.
United Fire Group Inc is engaged in the business of writing property and casualty insurance and selling annuities through a network of independent agencies. The company's only operating segment is property and casualty insurance, which includes commercial lines insurance, personal lines insurance, and assumed reinsurance. The primary source of revenue is premium and investment income.